Interferon (IFN) was the first cytokine discovered 50 years ago, with a wide range of biological properties, including immunomodulatory, proapoptotic and antiangiogenic activities, that rapidly raised interest in its therapeutic use in malignancies. IFN-receptor characterization was also pivotal in the discovery of the JAK/STAT signaling pathway. Among the large IFN family, mainly one of the type I IFN, IFN-a2, is used in therapy. Many clinical trials have shown remarkable efficacy of IFN-a in bcr-abl-negative myeloproliferative neoplasms (MPNs), especially polycythemia vera (PV), and essential thrombocythemia (ET). IFN-a induces about 80% of hematological responses in those diseases and is able to reduce splenomegaly, as well as relieve pruritus and other constitutional symptoms. Yet its use was limited by toxicity, leading to early treatment discontinuation in about 20% of the patients. However, its lack of leukemogenic potential and its possible use during pregnancy have already made IFN-a the drug of choice for younger MPN patients. In addition, several studies have shown a probably selective effect of IFN-a on PV and ET clones, as shown by cytogenetic remissions, reversions to polyclonal hematopoiesis, and more recently by induction of JAK2V617F complete molecular remissions in PV which may widen the indications of IFN-a in JAK2-mutated MPN.
Introduction
Interferon (IFN) was the first cytokine discovered, identified 50 years ago by Isaacs and Lindenmann. 1 They found a secreted factor produced by the influenza virus-infected chick cells able to transfer a virus-resistant state to previously uninfected cells. This factor was named IFN because of its ability to interfere with viral growth. IFNs were rapidly found to be produced in many animals, tissues and cells. About 10 mammalian IFN species have been discovered, including seven in humans (Table 1) . 2 IFNs belong to the class 2 a-helical cytokines that have existed in early chordates for about 500 million years, 3 and they have important functions in innate and adaptative immunity, which raised interest in their therapeutic use. The production and purification of human leukocyte IFNs obtained after infection of human white blood cells (WBCs) with viruses already allowed their use in clinical trials in the late 1970s. 4 Such preparation, however, did not allow complete purity, and although leukocyte IFN consisted predominantly of IFN-a, small amounts of other IFN species were also present. Later on, the cloning of recombinant human IFN-a and -b in 1980 allowed the production of large amounts of IFN for characterization, biological activity studies and clinical trials. [5] [6] [7] It is only 20 years after their discovery that two IFN species, IFN-a and -b, could be purified satisfactorily using high-performance liquid chromatography allowing their analysis and characterization. 8 
The IFN family
The human family of IFNs includes seven species (Table 1) . 8 IFN proteins are historically characterized as type I (or viral) IFN and type II (or immune) IFN. The latter type is composed of a unique member, IFN-g. Both type I and type II IFNs exert their actions through cognate receptor complexes, IFNAR and IFNGR, respectively, present on cell surface membranes. 9, 10 In addition, novel interleukin 10-related cytokines, now known as type III IFN or IFN-l, display activities and functions much similar to those of type I IFNs, although they signal through different receptor complexes. The most important and best studied among the type I IFNs is IFN-a.
IFN-a genes, receptors and signaling
The human IFN-a family comprises 14 genes, including 2 pseudo-genes or allelic forms (IFNAP22 and IFNA10). Thus in all, there are 13 proteins expressed from these genes, but only 12 distinct IFN-a and allelic forms (the protein produced from IFNA13 gene being identical to that produced from IFNA1). One of them, IFN-a2, has been very predominantly used as a therapeutic agent to date.
Interferons elicit many biological effects that can even be opposite in different cell types. For example, type I IFN inhibits proliferation and is proapoptotic for many cell types, 11 and yet it prolongs the survival of memory T cells. 12 Such a functional diversity can, at least in part, be explained by the diversity of the IFN receptor itself and of the signaling pathways that it may use. In addition, the early availability of recombinant IFNs offered an opportunity to investigate how cytokines induce gene expression, culminating in the discovery of the Janus kinase (JAK)/ signal transducers and activators of the transcription (STAT) signaling pathway.
The type I IFN receptor (IFNAR) complex is unique among cytokine receptors in the number of cognate ligands, including the 13 IFN-a subtypes, as well as the b, o, e and k species. IFNAR comprises two components, IFNAR1 and IFNAR2, with multiple isoforms. These type I IFN receptors are distinct from those required for the type II IFN-g (IFNGR1 and IFNGR2) and type III IFNs (IFNLR and IL10Rb). Nevertheless, genes encoding a component of each type of IFN receptor, namely IFNAR1, IFNAR2, IFNGR2 and IL10Rb, are located on human chromosome 21q22.1 in a cytokine receptor gene cluster.
Conventional type I IFN receptor comprises IFNAR1 and IFNAR2c, a long transmembrane isoform of IFNAR2. IFN binding to this complex induces activation by cross-phosphorylation of receptors and pre-associated JAKs in their cytoplasmic portions: Tyk2, associated with IFNAR1, and Jak1, associated with IFNAR2c. This provides docking sites on the receptor complex for STAT-1 and -2 proteins, which are in turn phosphorylated, dissociate from the receptor, and form homoand heterodimers. Activated STAT-1/STAT-2 heterodimers translocate to the nucleus and associate with IRF-9 (IFN regulatory factor-9) to form the trimeric ISGF-3 (IFN-stimulated gene factor-3) complex that binds to the ISRE (IFN-stimulated response element) enhancer family element within the promoters of IFN-regulated genes, leading to their transcription.
However, diversity of IFNAR signaling is probably achieved, in part, by the activation of other pathways including other STATs (in particular STAT-3) and non-STAT proteins. 11 These alternative signaling pathways include CrkL, Rap1, MAPkinases, Vav, RAC1, PI 3-kinase, IRS1 and -2, PMRT1 and Sin1.
An alternative mechanism of signaling, known as transsignaling, may be promoted by the soluble isoform of IFNAR2 (sINAR2a), as it has been shown that sIFNAR2a could bind IFN-a and transduce signals through IFNAR1. However, several other functions can be attributed to sIFNAR2a. Indeed, it may also act as a negative regulator of IFN signaling by the 'trapping' of circulating IFN molecules, or have a carrier function increasing the stability of bound IFNs.
The third isoform of IFNAR2 is IFNAR2b, a short transmembrane chain that may act as a dominant negative regulator of IFN signaling by binding ligand but not transducing signals, owing to its short intracellular portion.
Some mechanisms also exist to downregulate IFN signaling. Indeed, if the diversity of signals generated by IFNs aim at protecting the host against infection and malignant transformation, disproportionate signaling may be harmful by inducing leukopenia and autoimmune manifestations. Several negative regulatory molecules have been identified including SOCS-1 (suppressor of cytokine signaling-1), UBP43 (a type I IFN-inducible cysteine protease) and SHP-2. SOCS-1 inhibits IFN signaling by binding the C-terminal region of IFNAR1 and blocking the interaction with Tyk2; UBP43 blocks the JAK1/ IFNAR2 interaction, whereas SHP-2 is implicated in nuclear STAT dephosphorylation, which appears to be critical for STAT nuclear export, another mechanism of regulation of STAT activity. SOCS proteins are also thought to regulate JAKs activity by binding to their JH1 catalytic loop and targeting those kinases for degradation.
Activities and therapeutic use of IFNs
Interferons have a wide range of biological activities. They stimulate cytotoxic activity of several immune cells (T cells, natural killer cells, monocytes, macrophages, dendritic cells); 13 increase the expression of tumor-associated surface antigens and other surface molecules such as major histocompatibility complex (MHC) class I antigens, amplifying the recognition of infected or transformed cells by immune effectors, 14 induce and/ or activate proapoptotic genes and proteins including TRAIL, caspases, Bak and Bax; repress antiapoptotic genes such as Bcl-2, IAP (inhibitor of apoptosis protein); modulate cell differentiation and display antiangiogenic activity. 2 Accordingly, evaluation of IFNs as therapeutic agents (either alone or as adjuvant in combination with other therapies) focused mainly on cancers and viral diseases.
The US Food and Drug Administration approved human IFN-a2a and IFN-a2b (allelic versions of IFN-a2) in 1986 for the treatment of hairy cell leukemia. About 10 years later, IFN-b1a and IFN-b1b were approved for the treatment of multiple sclerosis. Clinical trials for IFN-a, before and after approval, focused on cancers and viral diseases. To date, IFN-a is approved for the treatment of hairy cell leukemia, malignant melanoma, follicular lymphoma, condylomata acuminata (genital warts), AIDS-related Kaposi sarcoma, and chronic hepatitis B and C. In addition, the use of IFN-a is frequent in many cancers, especially in bladder and renal cancers.
Rationale for IFN-a in the treatment of myeloproliferative neoplasms
Many activities of IFN-a provide a rationale for its use as therapy in myeloproliferative neoplasms (MPNs). First, IFN-a inhibits in vitro proliferation of hematopoietic progenitors. It has been shown that IFN-a could markedly reduce the colony-forming ability of erythroid, granulocytic and megakaryocytic progenitors in polycythemia vera (PV) and primary myelofibrosis (PMF). [15] [16] [17] Some of these in vitro studies even suggested that clonal MPN progenitors may be more sensitive to IFN-a than their normal counterparts. This possibly selective effect on the MPN clone is further supported by several in vivo studies showing reversion from monoclonal to polyclonal patterns of hematopoiesis (based on X-chromosome inactivation pattern studies) or disappearance of a chromosomal abnormality present before treatment in IFN-a-treated patients. [18] [19] [20] [21] Using quantification of JAK2V617F mutated alleles in circulating granulocytes as a marker of minimal residual disease, our group could also show that IFN-a was able to markedly decrease the proportion of circulating mutated cells. 22, 23 The megakaryocytic lineage seems particularly sensitive to IFN-a, with clear morphological and biochemical changes of megakaryocytes in IFN-treated patients. 24 Furthermore, IFN-a is able to directly repress megakaryopoiesis by inhibiting thrombopoietin-induced Mpl receptor signaling. 25 Finally, IFN-a antagonizes platelet-derived growth factor and inhibits the growth of marrow-derived fibroblasts, two activities that may be useful to treat myelofibrosis. Although the exact mechanisms of action of this cytokine on MPN clones are unknown, IFN-a could theoretically eradicate the MPN clone in selected cases by acting at the level of the hematopoietic stem cell, as described above on the one hand, and by enhancing the autologous immune response against transformed cells on the other hand.
SPOTLIGHT

Results of clinical trials using IFN-a in MPN
Clinical trials have shown the clear efficacy of IFN-a in the treatment of all types of MPN. This review will focus on the three main Ph-negative MPNs: PV, essential thrombocythemia (ET) and PMF. It will not analyze IFN-a effects in other MPNs, including chronic myelogenous leukemia, hypereosinophilic syndromes and systemic mastocytosis. The pioneer study of Silver in 1988 was followed by many studies showing the clinical efficacy of IFN-a in controlling myeloid proliferation and relieving pruritus and other constitutional symptoms in PV. 26 Similar efficacy was at the same time shown in ET. 27, 28 Many clinical studies have been performed since those first works, using various commercial forms of IFN-a. It can be noted that none of these forms is registered as yet by FDA, EMEA or the health agencies of other countries for Ph-negative MPNs. Most of the studies published to date used standard IFN-a 2a or 2b that were the first ones available for therapy. There was no biological evidence to anticipate better efficacy of one of those isoforms over the other in MPNs, and, indeed, the efficacy and toxicity profiles of these two drugs when used in Ph-negative MPNs were similar (Tables 2-4) .
More recently, pegylated forms have been developed. The addition of a polyethyleneglycol (peg) tail produces several benefits, including enhanced plasma half-life, lower toxicity, and increased drug stability and solubility, without affecting therapeutic activity. 60 Changes attributed to IFN pegylation translated into improvement for patients, mainly because of longer intervals between administrations (weekly instead of every 24-48 h) . Surprisingly, although pegylation of drugs usually results in a certain decrease in side effects, because of the reduced relative peak concentration after each injection, such benefit was not found for IFN as studies comparing standard versus pegylated IFN in hepatitis and chronic myelogenous leukemia patients showed similar rates of toxicity and treatment withdrawal using one or the other form. 61, 62 More than 700 PV, ET or PMF treated with IFN have been published, as shown in Tables 2, 3 and 4, summarizing IFN studies that included more than 10 patients. The meta-analysis of those studies is difficult. First, various forms of IFN-a were used, and one cannot exclude (even though it is unlikely) a different effect of those forms on the response rate and/or disease evolution. Furthermore, heterogeneous response criteria were used. In PV studies, reduction of phlebotomy requirement was always part of the response criteria. However, in some of those studies, complete response required only control of the hematocrit (Ht) without phlebotomies, whereas in others, normalization of platelet count, disappearance of splenomegaly, and resolution of disease-related symptoms such as pruritus were also required. In ET studies, complete response definition always included normalization of platelet count. Harmonization of response criteria to therapy in PV and ET, as made for PMF, 63, 64 would be very useful, and several groups, especially the MPN working group of the European LeukemiaNet, are currently working on such consensus response criteria to be used in future studies.
The results of those studies show that IFN-a is efficient for controlling myeloproliferation in PV and ET. In almost all studies, IFN-a was able to rapidly normalize platelet counts and leukocytosis as well as and reduce erythrocytosis, allowing reduction in the need for phlebotomies within a few months. In both diseases, an objective response was observed in about 80% of patients, including complete freedom from phlebotomies in PV in 60% of patients (Tables 2 and 3 ). In addition, IFN-a was also able to reduce PV-associated pruritus in a significant number of cases, and appears to be the most efficient drug for this symptom. However, toxicity of IFN was relatively important, leading to treatment discontinuation in almost one quarter of patients (see below). Although in vitro data suggested that IFN-a was a good candidate drug for treating bone marrow fibrosis, clinical trials in PMF have been disappointing (Table 4) . Almost no objective response was obtained in the 84 PMF patients reported. In 30% of the patients, spleen size decreased on treatment, whereas in almost the same proportion of patients, it did increase. Importantly, IFN toxicity in these studies was much higher than in PV or ET studies, leading to rapid treatment discontinuation (usually after 3-6 months only) in more than 50% of the patients. One of the main limiting toxicities of IFN in PMF, contrary to PV or ET studies, appeared to be the worsening of cytopenias.
SPOTLIGHT
Side effects of IFN-a
One of the main concerns regarding the wide use of IFN-a is toxicity. As shown in Tables 2 and 3 , the average rate of discontinuation because of toxicity in PV and ET trials with IFN-a was about 25%, almost half of those withdrawals occurring during the first year of therapy. A wide range of side effects has been reported with standard IFN-a.
Flu-like symptoms
Common flu-like symptoms are experienced by most patients and include headache, malaise, fever, chills, fatigue, myalgia, back and joint pain. These symptoms usually appear 1-3 h after administration, disappear within hours, and are generally manageable by the preventive use of paracetamol. In addition, they gradually decrease in intensity within a few weeks of treatment initiation. Surprisingly, although these symptoms have been recognized virtually since the discovery of IFN, their mechanism has not been identified clearly. They are clearly dose-dependent, and can be prevented or at least limited by starting IFN therapy at low doses, 42 but this may lead to the administration of suboptimal doses to control the disease. The frequency and intensity of those flu-like symptoms are usually less marked using pegylated forms of IFN.
Hematological toxicity
Hematological toxicity on erythroid and megakaryocytic lineages is commonly observed during IFN treatment of hepatitis patients (even sometimes requiring treatment with recombinant erythropoietin), but is very rare in PV and ET. In contrast, PMF patients often experience worsening of anemia or thrombocytopenia during IFN therapy, requiring treatment discontinuation in a substantial number of cases. 58 Neutropenia is also rarely reported as limiting toxicity in MPN treatment, again with the exception of PMF. The most common hematological side effect of IFN is lymphopenia, owing to a direct inhibitory effect on the production, recirculation and/or proliferation of lymphocytes, which is reversed after IFN treatment discontinuation. 8 However, lymphopenia has not been reported in MPN studies, perhaps because it was overlooked. On the other hand, clinical complications potentially related to lymphopenia (such as viral infections) were not reported in MPN studies.
SPOTLIGHT
Other toxicities
Some chronic IFN toxicities are difficult to prevent or control. They include fatigue and musculoskeletal pain, two of the most frequent reasons for treatment withdrawal. Depression is seen less often, but a history of depression or psychiatric disorder is indeed a contra-indication to IFN therapy. Less frequently reported, but often noticed by patients' entourage, are subtler mood changes, such as anxiety, irritability and sullenness, which may affect social life. Other rare side effects are skin toxicity (mild injection site reactions, or more generalized exanthema or urticaria), hair loss, as well as gastrointestinal toxicity including nausea, diarrhea and weight loss, liver, cardiac and neurologic toxicities.
An intriguing set of complications of chronic IFN therapy is the development of autoimmune abnormalities, ranging from single asymptomatic autoantibodies to overt autoimmune disease. Hypothyroidism, for example, is a rare but well-known complication of IFN treatment. However, other types of autoimmune abnormalities have been described in IFN-treated chronic myelogenous leukemia patients, including antinuclear autoantibodies, immune-mediated hemolysis or thrombocytopenia, polyarthritis, glomerulonephritis and connective tissue diseases. [65] [66] [67] [68] Mechanisms leading to the development of such abnormalities have not been clearly described, but they could include the direct immunomodulating properties of IFN or be initiated by a possible toxic effect in target organs, triggering self-directed immune response against altered cells. Some authors have raised the hypothesis that the development of autoimmune phenomena in IFN-treated chronic myelogenous leukemia patients could parallel and reflect the anti-leukemic efficacy of the drug, as patients presenting with autoimmune abnormalities had earlier and more frequent cytogenetic responses. 65, 66 The outcome of those immunological abnormalities is usually favorable, with autoantibodies disappearing after discontinuation of IFN-a, but they sometimes require specific treatment, such as hormone replacement in patients developing thyroiditis.
IFN-a and leukemic evolution
One major advantage of IFN-a is that it clearly appears to be non-leukemogenic, especially when compared with most available cytoreductive agents. Indeed, concern has appeared in recent years in MPNs regarding the long-term risk of hematological evolution to acute leukemia and myelodysplastic syndromes (AL/MDS). Increased risk of AL/MDS has been found to be associated with the use of alkylating agents and radioactive phosphorus in randomized clinical trials. [69] [70] [71] [72] By contrast, a leukemogenic potential of hydroxyurea (HU) has not been shown in clinical trials, although there is evidence showing that the sequential use of HU and other cytoreductive drugs (alkylating agents, radioactive phosphorus) increases the risk of AL/MDS. [72] [73] [74] [75] In addition, several retrospective studies did not find an increased risk of AL in PV and ET treated with HU alone, [76] [77] [78] and similar conclusions were drawn from a recent meta-analysis of HU therapy in sickle cell anemia. 79 Still, very long-term results of prospective studies in HU-treated MPN patients with more than 10 years of follow-up showed a cumulative incidence of AL/MDS of more than 10% beyond 12 years of follow-up, suggesting that the risk of leukemic evolution could be higher than reported earlier in studies with shorter follow-up. 80 The relative contribution of HU and of a natural, very long-term evolution of the disease in the pathogenesis of those late AL/MDS remains unclear. Those findings have however led published guidelines in ET and PV to recommend the use of clearly non-leukemogenic drugs such as IFN-a in younger patients requiring cytoreductive therapy. 81, 82 Has IFN-a a selective effect on myeloproliferative clones?
Just as for all hematological malignancies, a future primary objective of Ph-negative MPN treatment should be cure, a goal that currently cannot be achieved with the available drugs that have never been shown to positively influence the disease natural history. The situation may change with the development of JAK2 inhibitors, 83 but to date only IFN-a has been able to induce cytogenetic remissions or reversion from monoclonal to polyclonal hematopoiesis in some patients, [18] [19] [20] [21] suggesting that it could eradicate the malignant clone and possibly cure the disease in selected cases. By monitoring the JAK2V617F mutation in PV patients treated with peg-IFNa-2a, we also showed that the V617F mutation could be reduced to undetectable levels (using a PCR assay with 1% sensitivity) in circulating granulocytes in 24% of patients ('molecular remission'). 22 Such reduction of the JAK2 mutated clone with IFN-a may help explain reported cases of hematological remissions in ET and PV patients lasting for months after treatment discontinuation (without further cytoreductive therapy). 84, 85 We also found that some of those molecular responses could persist for more than 18 months after peg-IFNa-2a discontinuation. 22 Reduction of the JAK mutated clone, however, does not imply a cure of the disease. First, the sensitivity limit of the technique we used (1%) remained low. Furthermore, studies comparing clonality (based on X-chromosome inactivation patterns or coexisting cytogenetic abnormalities) to JAK2 mutant allele frequency suggest that JAK2V617F could be a secondary genetic event in some PV patients. [86] [87] [88] [89] If so, the elimination of JAK2V617F would only reflect the evolution of subclones. On the other hand, a theoretical advantage of IFNa compared to more specific inhibitors is that, being 'nonspecific' of any genetic alteration, it may have some activity against MPN clones regardless of their underlying molecular defects.
Reduction of the JAK2 mutated clone may, however, affect disease evolution. For example, the percentage of the circulating mutated JAK2 allele was shown to be significantly higher in PV and ET patients who developed myelofibrosis, and may also be significantly higher in patients who develop vascular complications. 90, 91 Some authors suggested that IFN-a could delay myelofibrosis development in PV patients 42 based on in vitro data, a benefit that could be mediated by reduction of the proportion of JAK2V617F mutated cells. In addition, the selective effect of IFN-a on mutated granulocytes may affect the incidence of thrombosis, as it has been shown that leukocyte SPOTLIGHT activation and hemostatic changes were correlated with the presence of JAK2 mutation. 90, 92, 93 Accordingly, the incidence of thrombosis in IFN-a-treated patients was consistently found to be lower than expected during follow-up. 42, 84, 85 Recently, two studies found that HU was also able to induce molecular responses in 50-70% of small numbers of newly diagnosed PV (n ¼ 9 and n ¼ 7, respectively) and ET (n ¼ 9 and n ¼ 17, respectively) patients, suggesting a specific effect of HU on the JAKV617F clone. 94, 95 Those results are in contrast, however, with the absence of cytogenetic remission or reversion to polyclonal hematopoiesis reported with this drug, although it has been used for decades in MPN. In our experience in 20 newly diagnosed MPN patients treated with HU, we also observed in 6 of them a reduction in the proportion of the V617F circulating allele during the first months of therapy. However, the percentage of V617F re-increased in all of them during the second year of therapy, even returning to the initial JAK2V617F level in five (B Cassinat, personal communication). In the two studies that showed a reduction of V617F on HU, 94 ,95 a similar re-increase of the mutant allele was seen in some patients tested after the first year of treatment, an evolution not observed in IFNa-treated patients, even after 31 months of median followup. 22 The reduction in the proportion of the JAK2V617F mutated cell observed with HU during the first months of therapy could be due to the initial hypersensitivity of mutated cells to HU, already reported in ET and in PMF.
96,97
Conclusion and perspectives
Many studies over the last 20 years have shown remarkable efficacy of IFN-a in PV and ET, but its use remained limited in clinical practice, due to side effects, and maybe in some cases to the lack of experience of physicians with the management of IFN-a treatment. Indeed, in expert hands, low toxicity with the long-term use of this drug has been reported. 42 Although many biological properties of IFNa may account for its efficacy in MPN, the exact mechanisms are unknown. The time interval between the hematological and molecular responses we observed with peg-IFNa-2a in PV suggests that the direct cytotoxic and antiproliferative properties of IFN are responsible for the rapid hematologic response (within 3 months in about 90% of the patients), whereas immune-mediated mechanisms could be involved in molecular response, achieved later (during the second year of therapy in the majority of case). 22 To date, indications of IFN-a for the treatment of PV and ET have remained generally limited to high-risk patients younger than 40 years as well as to pregnancy in published guidelines. 81, 82 Indeed, when cytoreduction is necessary during pregnancy, many publications have documented the safety of IFN-a in MPN mothers as well as fetuses. 98, 99 However, there are very limited data available on the long-term safety of IFN-a in children exposed to this drug during pregnancy. Recent results, however, suggest that indications of treatment with IFN-a should be larger. First, the possibly higher incidence of progression to MDS and AL in the very long term in PV and ET than assessed earlier 80 suggests that non leukemogenic drugs such as IFNa may be more largely used in those disorders by comparison with chemotherapeutic agents. An additional advantage of IFN-a may be its ability to specifically reduce the MPN clone in a large proportion of PV patients, and even to induce complete molecular remissions (assessed by disappearance of the JAK2 mutation). 22 This reduction of the JAK2 mutated clone may be associated with reduction in the risk of vascular complications and disease progression. 90, 92, 93 Confirmation of those findings may widen the indications of IFN-a in JAK2-mutated PV and ET, without restricting treatment to patients at high risk of vascular complications. The current development of JAK2 inhibitors raises the hope that molecularly targeted therapy may benefit MPN patients by reducing the kinase hyperactivity that may lead to more aggressive disease with higher incidence of vascular events and of hematological evolution. Future clinical trials with JAK2 inhibitors will have to compare them with IFN-a, currently the most efficient molecule for inducing high rates of molecular response, and include vascular events and hematological transformation as end points (in addition to hematological and molecular responses). One should also keep in mind that the vast majority of ET and PV have excellent response rates and important reduction of the vascular risks using conventional 'palliative' therapies such as HU. The use of much more expensive drugs with unknown long-term risk could be justified only if they can cure or significantly alter the natural history of those diseases and, in particular, the very long-term risk of evolution to AL/MDS.
